TY - JOUR T1 - Proton magnetic resonance spectroscopy in frontotemporal lobar degeneration-related syndromes JF - medRxiv DO - 10.1101/2021.01.11.21249589 SP - 2021.01.11.21249589 AU - Alexander G Murley AU - Kamen A Tsvetanov AU - Matthew A Rouse AU - P Simon Jones AU - Katrine Sværke AU - Win Li AU - T Adrian Carpenter AU - James B Rowe Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/13/2021.01.11.21249589.abstract N2 - Objective To measure cortical metabolite deficits in vivo in syndromes associated with frontotemporal lobar degeneration, in relation to cognitive and behavioral change.Methods Sixty patients were recruited with a clinical syndrome associated with frontotemporal lobar degeneration (behavioral variant frontotemporal dementia n=11, progressive supranuclear palsy n=26, corticobasal syndrome n=11, primary progressive aphasias n=12), and 38 age- and sex-matched healthy controls. We measured nine metabolites in the right inferior frontal gyrus, superior temporal gyrus and right primary visual cortex using 3T semi-laser magnetic resonance spectroscopy. Metabolite concentrations were corrected for age, sex, and partial volume. We related corrected metabolite concentrations to cognitive and behavioral measures using canonical correlation analysis.Results Metabolite concentrations varied significantly by brain region and diagnosis (region x metabolite x diagnosis interaction F(64)=1.73, p<0.001, corrected for age, sex, and atrophy within the voxel). N-acetyl aspartate and glutamate concentrations were reduced in the right prefrontal cortex in behavioral variant frontotemporal dementia and progressive supranuclear palsy, even after partial volume correction. The reduction of these metabolites was associated with executive dysfunction and behavioral impairment (canonical correlation analysis R=0.95, p<0.001).Conclusion Magnetic resonance spectroscopy confirms behaviourally relevant metabolite deficits including glutamate, in syndromes associated with frontotemporal lobar degeneration. Magnetic resonance spectroscopy may be a useful index of neurodegeneration, and highlight candidates for pharmacological treatment.Competing Interest StatementJ.B.R. serves as an associate editor to Brain and is a non-remunerated trustee of the Guarantors of Brain, Darwin College Cambridge, and the PSP Association (UK). He has provided consultancy to Asceneuron, Biogen, UCB and has research grants from AZ-Medimmune, Janssen, Lilly and WAVE as industry partners in the Dementias Platform UK. The other authors have no disclosures.Funding StatementThis work was funded by the Holt Fellowship (RG86564), the Guarantors of Brain (G101149), the Wellcome Trust (103838), the PSP Association, the Medical Research Council (SUAG/051 G101400), the National Institute for Health Research (NIHR) Biomedical Research Centre and Biomedical Research Unit in Dementia based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge (146281) and the Cambridge Centre for Parkinson Plus.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Cambridge Central Research Ethics Committee (REC 12/EE/0475)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised data are available on reasonable request for academic use, subject to restrictions required to protect participant confidentiality. ER -